Viral Vaccine Vectors in Personalized Medicine

Informacje na temat projektu

VIVAVE

Identyfikator umowy o grant: 737592

DOI

10.3030/737592

Projekt został zamknięty

Data podpisania przez KE 27 Stycznia 2017

Data rozpoczęcia 1 Lutego 2017

Data zakończenia 31 Grudnia 2018

Finansowanie w ramach

• EXCELLENT SCIENCE - European Research Council (ERC)

Koszt całkowity

€ 149 858,00

Wkład UE

€ 149 858,00

Koordynowany przez

HELMHOLTZ-ZENTRUM FUR INFEKTIONSFORSCHUNG GMBH
Germany

Periodic Reporting for period 1 - VIVAVE (Viral Vaccine Vectors in Personalized Medicine)

Okres sprawozdawczy: 2017-02-01 do 2018-12-31

Podsumowanie kontekstu i ogólnych celów projektu

VIVAVE provided us with initial and vital information on the ability of a novel class of vaccine vectors. We have tested a vector that infects numerous types of human cells and expresses antigens in them, allowing recognition by CD8 T cells and their activation, but which due to its natural properties does not propagate itself in human cells. The vector was tested in several human cell and in coculture with human T cells. Testing of the vector in preclinical animal models will be continued through additional public funding, which was secured based on results from this the ERC PoC.